AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36180610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing of the femur
Number of subjects: 1
Study 32504701 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 267
Study 32504701 — intervention group
Group type: COMPARATOR
Intervention: Bolus midazolam
Number of subjects: 267
Study 32504701 — intervention group
Group type: COMPARATOR
Intervention: Titrated midazolam
Number of subjects: 267
Study 33306314 — intervention group
Group type: EXPERIMENTAL
Intervention: New superficial landmark for axillary venous approach
Number of subjects: 538
Study 33306314 — intervention group
Group type: COMPARATOR
Intervention: Conventional landmarks for subclavian venous approach
Number of subjects: 538
Study 34561195 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (yes)
Number of subjects: 600
Study 34561195 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (no)
Number of subjects: 600
Study 34561195 — intervention group
Group type: EXPERIMENTAL
Intervention: Short antiplatelet therapy (1 month)
Number of subjects: 600
Study 34561195 — intervention group
Group type: COMPARATOR
Intervention: Prolonged antiplatelet therapy (12 months)
Number of subjects: 600
Study 34561195 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 600
Study 34678987 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose neubotulinum toxin A (Neu-BoNT-A)
Number of subjects: 52
Study 34678987 — intervention group
Group type: COMPARATOR
Intervention: Low-dose abobotulinum toxin A (Abo-BoNT-A)
Number of subjects: 52
Study 32109743 — intervention group
Group type: EXPERIMENTAL
Intervention: Total crystalloid volume (TCV) below 3 L
Number of subjects: 83685
Study 32109743 — intervention group
Group type: EXPERIMENTAL
Intervention: Total crystalloid volume (TCV) above 6 L
Number of subjects: 83685
Study 32109743 — intervention group
Group type: EXPERIMENTAL
Intervention: Total crystalloid volume (TCV) for bariatric surgery
Number of subjects: 83685
Study 32109743 — intervention group
Group type: EXPERIMENTAL
Intervention: Total crystalloid volume (TCV) within ERAS guidelines
Number of subjects: 83685
Study 33843370 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-behavioral activation (Tele-BA)
Number of subjects: 279
Study 33843370 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-problem-solving therapy (Tele-PST)
Number of subjects: 279
Study 33843370 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-BA and Tele-PST
Number of subjects: 279
Study 35419960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 208
Study 35419960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 32811627 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual counseling and monitoring via telephone calls and/or video chat sessions
Number of subjects: 0
Study 33616641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 33616641 — intervention group
Group type: COMPARATOR
Intervention: Low-dose mycophenolate mofetil
Number of subjects: 0
Study 36366886 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-122 100 mg, twice daily for 28 days
Number of subjects: 131
Study 36366886 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 28 days
Number of subjects: 131
Study 32598700 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy (ET) with the addition of the prebiotic Zakofalk (inulin + butyrate)
Number of subjects: 120
Study 32598700 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy (ET) with the addition of probiotics (lacto- and bifidobacteria)
Number of subjects: 120
Study 32598700 — intervention group
Group type: COMPARATOR
Intervention: Eradication therapy (ET) without the addition of pre- or probiotics
Number of subjects: 120
Study 33923663 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (Gasteel Plus®)
Number of subjects: 0
Study 33923663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32749938 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus bevacizumab (arm A)
Number of subjects: 241
Study 32749938 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 alone (arm B)
Number of subjects: 241
Study 35039277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus leuprorelin
Number of subjects: 40
Study 35039277 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 40
Study 32809153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological interventions for early-stage PD (specific interventions not detailed)
Number of subjects: 0
Study 32809153 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (potential for use in PD)
Number of subjects: 0
Study 32809153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lessons learned from Alzheimer's research
Number of subjects: 0
Study 32639373 — intervention group
Group type: EXPERIMENTAL
Intervention: Omegawave (OW) device
Number of subjects: 65
Study 32639373 — intervention group
Group type: COMPARATOR
Intervention: Strenuous exercise
Number of subjects: 65
Study 32639373 — intervention group
Group type: COMPARATOR
Intervention: Rest day
Number of subjects: 65
Study 35360106 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic dose 2.5 × 10^9 CFU/day (n = 18)
Number of subjects: 56
Study 35360106 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic dose 1 × 10^10 CFU/day (n = 18)
Number of subjects: 56
Study 35360106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 56
Study 33850467 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment
Number of subjects: 334
Study 33850467 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment at outpatient clinic
Number of subjects: 334
Study 33199470 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 107
Study 32055717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HF) - 58 Gy/40 fractions, twice daily
Number of subjects: 331
Study 32055717 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CF) - 51 Gy/20 fractions, once daily
Number of subjects: 331
Study 35687702 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program using an elastic band three days a week for 12 weeks
Number of subjects: 80
Study 33548487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand pain
Number of subjects: 13
Study 33548487 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee pain
Number of subjects: 13
Study 33212780 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary intervention (Mediterranean or low-fat diets)
Number of subjects: 215
Study 35803550 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery (GMI)
Number of subjects: 50
Study 35803550 — intervention group
Group type: COMPARATOR
Intervention: Structured Exercise (SE)
Number of subjects: 50
Study 33906450 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy
Number of subjects: 51
Study 33906450 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 51
Study 33906450 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 33906450 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control and sham)
Number of subjects: 51
Study 33176569 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-based case definitions of lupus nephritis (LN)
Number of subjects: 981
Study 33176569 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 code for lupus nephritis (LN)
Number of subjects: 981
Study 32994159 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 6952
Study 32994159 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 6952
Study 32994159 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6952
Study 32994159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6952
Study 32385851 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide 10 or 30 mg every 28 days (minimum/maximum dose: 5/40 mg)
Number of subjects: 150
Study 32385851 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide
Number of subjects: 150
Study 34023289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided trigeminal nerve block (UGTNB) with general anesthesia
Number of subjects: 40
Study 34023289 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GEA)
Number of subjects: 40
Study 33059798 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion programs and policies in the workplace
Number of subjects: 26
Study 36371904 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to order HPV‐ss kit (opt‐in)
Number of subjects: 6000
Study 36371904 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly mailed HPV‐ss kit (send‐to-all)
Number of subjects: 6000
Study 36371904 — intervention group
Group type: COMPARATOR
Intervention: Reminder letter (control)
Number of subjects: 6000
Study 33646255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practicum experiences
Number of subjects: 0
Study 33646255 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time clinical education experiences
Number of subjects: 0
Study 32972007 — intervention group
Group type: EXPERIMENTAL
Intervention: SaBang-DolGi walking exercise program for 12 weeks
Number of subjects: 40
Study 32972007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 35176206 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 40 mg
Number of subjects: 32
Study 35176206 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 80 mg
Number of subjects: 32
Study 35176206 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (both doses)
Number of subjects: 32
Study 35176206 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated efficacy for OwH and HR Chinese patients
Number of subjects: 32
Study 35809371 — intervention group
Group type: EXPERIMENTAL
Intervention: V590 (5.55 × 10⁷ pfu)
Number of subjects: 232
Study 35809371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 35809371 — intervention group
Group type: EXPERIMENTAL
Intervention: V590 (all dose levels)
Number of subjects: 232
Study 34022476 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 0
Study 34022476 — intervention group
Group type: COMPARATOR
Intervention: Standard CT model
Number of subjects: 0
Study 34022476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiomics-standard CT model
Number of subjects: 0
Study 32388529 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care physician consultation
Number of subjects: 5727
Study 32388529 — intervention group
Group type: COMPARATOR
Intervention: Dentist consultation
Number of subjects: 5727
Study 34472117 — intervention group
Group type: EXPERIMENTAL
Intervention: Vatinoxan (0.1 mg/kg)
Number of subjects: 12
Study 34472117 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 32861668 — intervention group
Group type: EXPERIMENTAL
Intervention: EX2 (5 times a week, twice daily, 50 sessions; n=286)
Number of subjects: 641
Study 32861668 — intervention group
Group type: EXPERIMENTAL
Intervention: EX1 (5 times a week, once daily, 25 sessions; n=272)
Number of subjects: 641
Study 32861668 — intervention group
Group type: COMPARATOR
Intervention: CON (low-intensity standard care, 25 sessions; n=83)
Number of subjects: 641
Study 32861668 — intervention group
Group type: EXPERIMENTAL
Intervention: EX2 and EX1
Number of subjects: 641
Study 35944766 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1800
Study 35944766 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800
Study 35944766 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted mortality in N‐E
Number of subjects: 1800
Study 35944766 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted mortality in S‐E
Number of subjects: 1800
Study 33852251 — intervention group
Group type: EXPERIMENTAL
Intervention: CAL/BDP cream
Number of subjects: 796
Study 33852251 — intervention group
Group type: COMPARATOR
Intervention: CAL/BDP TS
Number of subjects: 796
Study 33852251 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 796
Study 36343597 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing low calorie, aesthetically pleasing foods on Instagram
Number of subjects: 436
Study 36343597 — intervention group
Group type: COMPARATOR
Intervention: Control condition featuring travel images
Number of subjects: 436
Study 34106240 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based matching to good-fitting therapists
Number of subjects: 218
Study 34106240 — intervention group
Group type: COMPARATOR
Intervention: Case assignment as usual (CAU)
Number of subjects: 218
Study 35294415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20mg once-daily
Number of subjects: 81
Study 35294415 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30mg once-daily
Number of subjects: 81
Study 32774912 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 42
Study 32774912 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg)
Number of subjects: 42
Study 34085549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal mesotherapy
Number of subjects: 148
Study 34085549 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexketoprofen
Number of subjects: 148
Study 33276738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking status (current smokers at baseline)
Number of subjects: 150
Study 33276738 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV treatment adherence
Number of subjects: 150
Study 33276738 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV treatment completion
Number of subjects: 150
Study 33276738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virologic response (SVR)
Number of subjects: 150
Study 33276738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking after HCV treatment
Number of subjects: 150
Study 35588897 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran 10 mg q12 weeks
Number of subjects: 281
Study 35588897 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran 75 mg q12 weeks
Number of subjects: 281
Study 35588897 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran 225 mg q12 weeks
Number of subjects: 281
Study 35588897 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran 225 mg q24 weeks
Number of subjects: 281
Study 35588897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 33677724 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Outpatient Clinic Programme (OOCP)
Number of subjects: 239
Study 33677724 — intervention group
Group type: COMPARATOR
Intervention: Traditional Scheduled Routine Follow-up (TSRF)
Number of subjects: 239
Study 36047138 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 100
Study 36047138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32423694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led 5-step deprescribing intervention
Number of subjects: 295
Study 32423694 — intervention group
Group type: COMPARATOR
Intervention: Active waitlist control
Number of subjects: 295
Study 33416226 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Splints Method
Number of subjects: 45
Study 33416226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early orthodontics)
Number of subjects: 45
Study 35536844 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gait training (RGT) using the Ekso robotic exoskeleton
Number of subjects: 128
Study 35536844 — intervention group
Group type: COMPARATOR
Intervention: Usual care gait training (UC) using traditional approaches such as manually assisted overground gait training and body weight–supported treadmill training (BWSTT)
Number of subjects: 128
Study 33886949 — intervention group
Group type: COMPARATOR
Intervention: Matrix support for six months, including face‐to‐face educational activities for health teams.
Number of subjects: 0
Study 33886949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no matrix support).
Number of subjects: 0
Study 36227234 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest Redistribution with Heavier Loads (RR + L): 4 sets of (2 × 5) repetitions with 90-second interset rest and 30-second intraset rest using 75% BS 1RM
Number of subjects: 8
Study 36227234 — intervention group
Group type: COMPARATOR
Intervention: Traditional Sets (TS): 4 sets of 10 repetitions with 120-second interset rest using 70% BS 1RM
Number of subjects: 8
Study 33785496 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 213
Study 33785496 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapist-led exercise therapy
Number of subjects: 213
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering medication
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering medications
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Any CVD prevention medication
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol control
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity targets
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control in high CVD risk
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol control in high CVD risk
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight control in high CVD risk
Number of subjects: 47841
Study 32065775 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering medication use in high CVD risk
Number of subjects: 47841
Study 35157768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry (EXENT&FLC‐MS)
Number of subjects: 223
Study 35157768 — intervention group
Group type: COMPARATOR
Intervention: Immunofixation (IFE)
Number of subjects: 223
Study 32350058 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 0
Study 32350058 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (antiplatelet medication such as aspirin or anticoagulation)
Number of subjects: 0
Study 36401465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D)
Number of subjects: 40
Study 36401465 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group N)
Number of subjects: 40
Study 34896053 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlearning module (MLM)
Number of subjects: 113
Study 34896053 — intervention group
Group type: COMPARATOR
Intervention: WISE‐MD™ module
Number of subjects: 113
Study 34896053 — intervention group
Group type: COMPARATOR
Intervention: Comparison of post-test1 scores
Number of subjects: 113
Study 34896053 — intervention group
Group type: COMPARATOR
Intervention: Pre-test and post-test2 scores comparison
Number of subjects: 113
Study 32901302 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for at least 4 hours
Number of subjects: 2091
Study 32901302 — intervention group
Group type: COMPARATOR
Intervention: Non-fasting (unrestricted consumption of liquids and solids)
Number of subjects: 2091
Study 32901302 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for at least 4 hours (subgroup analysis)
Number of subjects: 2091
Study 32901302 — intervention group
Group type: COMPARATOR
Intervention: Non-fasting (unrestricted consumption of liquids and solids) (subgroup analysis)
Number of subjects: 2091
Study 32042286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50 µg once daily
Number of subjects: 111
Study 32042286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 34510025 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval stair climbing (moderate‐ to high‐intensity)
Number of subjects: 28
Study 32659777 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan 0.4%
Number of subjects: 25
Study 32659777 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan 0.8%
Number of subjects: 25
Study 32659777 — intervention group
Group type: COMPARATOR
Intervention: Control (0% glucomannan)
Number of subjects: 25
Study 33129848 — intervention group
Group type: COMPARATOR
Intervention: tDCS (anodal, cathodal, or sham) for 20 min at 2 mA over the left dorsolateral prefrontal cortex (lDLPFC)
Number of subjects: 0
Study 33129848 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (cathodal)
Number of subjects: 0
Study 33129848 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (anodal)
Number of subjects: 0
Study 33129848 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 34763937 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg daily until progression or treatment discontinuation
Number of subjects: 59
Study 34494113 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP supplement
Number of subjects: 470
Study 34494113 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily iron‐folic acid tablet)
Number of subjects: 470
Study 33955348 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond consumption (1.5 oz daily with breakfast and as an afternoon snack)
Number of subjects: 134
Study 33955348 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual breakfast and afternoon snack routines)
Number of subjects: 134
Study 33595634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (200,000 IU)
Number of subjects: 240